Background: Liraglutide is a drug that may be useful in the pharmacological treatment of overweight and obesity, however, its effectiveness has not been evaluated systematically or its relationship with other drugs, so the objective of this study is to evaluate its effectiveness in comparison with other currently available management therapies in body weight reduction. Methodology: A systematic review and network meta-analysis were carried out. For the search, Medline, Embase and LiLaCS databases were used and controlled clinical trials published in English and Spanish were included, performing a qualitative and quantitative analysis of the information. Results: Twenty studies were included. According to the analysis of the direct comparison against placebo, Liraglutide achieved a weight loss of up to 5 kg in 6 months (mean difference -5.28 [-5.49, -5.07]) and against Orlistat, showed a higher proportion of patients with loss of 5% or more of body weight (OR 4.02 [2.14, 7.52]). In the indirect comparison, Lorcaserin OR 3.77 (95% CI 3.17, 4.44) and Topiramate / Phentermine OR 2.03 (95% CI 1.65, 2.55) showed a higher proportion of patients with loss of weight of 5% or more. The proportion of non-severe adverse reactions was higher with Liraglutide compared to the rest of the pharmacological therapies except Naltrexone / Bupropion. Conclusion: Liraglutide is an effective pharmacological option for the treatment of overweight/obesity. The direct analysis shows superiority against placebo and Orlistat. Indirect comparison shows that it is inferior to Topiramate / Phentermine and Lorcaserin, and superior to Metformin, Exenatide, Bupropion and Naltrexone / Bupropion.
